NCT07187531View on ClinicalTrials.gov

SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

159

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

November 30, 2027

Study Completion Date

December 31, 2028

Conditions
Type 1 Diabetes
Interventions
DRUG

High Dose SAB-142

High Dose SAB-142

DRUG

Low Dose SAB-142

Low Dose SAB-142

OTHER

Placebo

Placebo

All Listed Sponsors
lead

SAb Biotherapeutics, Inc.

INDUSTRY